Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3201531rdf:typepubmed:Citationlld:pubmed
pubmed-article:3201531lifeskim:mentionsumls-concept:C0184661lld:lifeskim
pubmed-article:3201531lifeskim:mentionsumls-concept:C0003233lld:lifeskim
pubmed-article:3201531lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:3201531lifeskim:mentionsumls-concept:C0124008lld:lifeskim
pubmed-article:3201531lifeskim:mentionsumls-concept:C0079365lld:lifeskim
pubmed-article:3201531lifeskim:mentionsumls-concept:C1709793lld:lifeskim
pubmed-article:3201531pubmed:issue4lld:pubmed
pubmed-article:3201531pubmed:dateCreated1989-1-25lld:pubmed
pubmed-article:3201531pubmed:abstractTextA fluorescence polarization immunoassay (FPIA) procedure for measuring isepamicin, a new aminoglycoside antibiotic, was evaluated. The range of the assay studied was from 0.3-50 micrograms/ml and the calibration curve can be stored for at least 32 days. There was no interference from hemoglobin (up to 400 mg/dl) and bilirubin (up to 20 mg/dl). Within-run precision on each 20 replicates at 5, 15, and 25 micrograms/ml yielded a coefficient of variation (CV) of 1.44-2.52%; between-run precision on analyses at 5, 15, and 25 micrograms/ml over five periods yielded a CV of 1.26-1.59%. Cross-reactivities of the assay system with tobramycin and amikacin were null, but that with gentamicin, of which isepamicin is a derivative, was approximately 14-29%. Data obtained by microbiological assay and FPIA and by high-performance liquid chromatography and FPIA correlated significantly, with coefficients of correlation being 0.980 (n = 70) and 0.965 (n = 39), respectively. The FPIA offers a rapid, efficient, and accurate system for therapeutic monitoring of isepamicin plasma levels.lld:pubmed
pubmed-article:3201531pubmed:languageenglld:pubmed
pubmed-article:3201531pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3201531pubmed:citationSubsetIMlld:pubmed
pubmed-article:3201531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3201531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3201531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3201531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3201531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3201531pubmed:statusMEDLINElld:pubmed
pubmed-article:3201531pubmed:issn0163-4356lld:pubmed
pubmed-article:3201531pubmed:authorpubmed-author:SuzukiYYlld:pubmed
pubmed-article:3201531pubmed:authorpubmed-author:SatoRRlld:pubmed
pubmed-article:3201531pubmed:authorpubmed-author:MizunoAAlld:pubmed
pubmed-article:3201531pubmed:authorpubmed-author:NakashimaMMlld:pubmed
pubmed-article:3201531pubmed:authorpubmed-author:YamazakiTTlld:pubmed
pubmed-article:3201531pubmed:authorpubmed-author:UematsuTTlld:pubmed
pubmed-article:3201531pubmed:issnTypePrintlld:pubmed
pubmed-article:3201531pubmed:volume10lld:pubmed
pubmed-article:3201531pubmed:ownerNLMlld:pubmed
pubmed-article:3201531pubmed:authorsCompleteYlld:pubmed
pubmed-article:3201531pubmed:pagination459-62lld:pubmed
pubmed-article:3201531pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:meshHeadingpubmed-meshheading:3201531-...lld:pubmed
pubmed-article:3201531pubmed:year1988lld:pubmed
pubmed-article:3201531pubmed:articleTitleEvaluation of a fluorescence polarization immunoassay procedure for quantitation of isepamicin, a new aminoglycoside antibiotic.lld:pubmed
pubmed-article:3201531pubmed:affiliationDepartment of Pharmacology, Hamamatsu University School of Medicine, Japan.lld:pubmed
pubmed-article:3201531pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3201531pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3201531pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3201531lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3201531lld:pubmed